Corient Private Wealth
MRTX

Corient Private Wealth’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Corient Private Wealth’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-640
Closed -$23.8K – 2194
2023
Q1 		$23.8K Sell
640
-9,885
-94% -$445K ﹤0.01% 1969
2022
Q4 		$477K Buy
+10,525
New +$681K ﹤0.01% 1156

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Corient Private Wealth's MRTX Position: Q2 2023 in Review

Corient Private Wealth sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2023, closing a stake of 640 shares — an estimated $23.8K sold.

Corient Private Wealth first reported a position in MRTX in Q4 2022 and held it in 2 quarters. The position peaked at $477K in Q4 2022. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

  • Corient Private Wealth reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Corient Private Wealth sold 640 Mirati Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $23.8K.
  • Corient Private Wealth first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Corient Private Wealth's Mirati Therapeutics, Inc. Common Stock position peaked at $477K in Q4 2022.
  • 207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Corient Private Wealth's 13F filing for Q2 2023, filed 10 Aug 2023.